Abstract
Indication
To establish the diagnosis of acromegaly when there is modest elevation of IGF-1 (< 2-fold upper limit of normal) with absent or equivocal clinical features [1].
Access provided by Autonomous University of Puebla. Download chapter PDF
Similar content being viewed by others
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
FormalPara Indication:To establish the diagnosis of acromegaly when there is modest elevation of IGF-1 (< 2-fold upper limit of normal) with absent or equivocal clinical features [1]
FormalPara Preparation:10 h fasting
FormalPara Materials Needed:Glucose drink 75 g
FormalPara Assay for GH:Immunoenzymatic assay
FormalPara Precautions:Patients may complain of nausea.
FormalPara Interpretation:Diagnosis of acromegaly: Using ultrasensitive assays, a GH suppression to < 0.4 ng/ml is considered the gold standard test to rule out acromegaly [2]. The GH cutoff value may vary based on the assay used. The authors use a GH cutoff value < 0.2 ng/mL as a normal response, using a immunoenzymatic assay at Cleveland Clinic [1].
A GH level < 1 ng/mL early after surgery, in the absence of presurgical usage of somatostatin analogs, predict long-term remission [3].
-
Endocrinologists should be familiar with the assays used in their laboratories, including the expected normal nadir GH level after oral glucose e [4].
-
Elevated IGF-1 levels more than twice the upper limit of normal in patients with clinical features suggestive of an underlying acromegaly, are usually sufficient to establish the diagnosis [1].
-
Failure of adequate suppression or a paradoxical rise in GH level can be seen in starvation, anorexia nervosa, and chronic renal failure, but these conditions are typically associated with low IGF-1 levels.
-
GH levels during OGTT have not been well studied in patients with diabetes mellitus, and in those on estrogen . In the authors’ experience, patients with diabetes who are not poorly controlled achieve GH levels during OGTT similar to those without DM [5].
A paradoxical GH secretary response to glucose may be seen in premature infants, children of tall stature, and adolescents [6].
Completed as outpatient.
-
1.
Establish saline lock.
-
2.
Check POC BG.
-
3.
Draw baseline growth hormone.
-
4.
Give glucose 75 g orally (glucose drink).
-
5.
Draw glucose and growth hormone levels at 30, 60, 90, and 120 min [7].
-
6.
(Include insulin levels at baseline, 30, 60, 90, and 120 min only if requested).
Patient label: ▁
Physician name and signature: ▁
RN performing the procedure: ▁
Additional orders by physician: ▁
GH suppression test | Baseline | 30 min | 60 min | 90 min | 120 min |
---|---|---|---|---|---|
Glucose | |||||
GH |
References
Subbarayan SK, Fleseriu M, Gordon MB, et al. Serum IGF-1 in the diagnosis of acromegaly and the profile of patients with elevated IGF-1 but normal glucose-suppressed growth hormone. Endocr Pract. 2012;18(6):817–25.
Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK. American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. Endocr Pract. 2011;17:1–44.
Minuto F, Resmini E, Boschetti M, et al. Assessment of disease activity in acromegaly by means of a single blood sample: Comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system. Clin Endocrinol (Oxf). 2004;61(1):138–44.
Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement: Medical management of acromegaly. Eur J Endocrinol . 2005;153(6):737–40.
Dobri GA, Faiman C, Kennedy L, et al. Is the GH Nadir value during OGTT reliable in diagnosing acromegaly in patients with altered glucose metabolism? Poster Board SAT-128, Endo 2013. https://Endo.confex.com/endo/2013endo/webprogram/Paper7607.html.
Hattori N, Shimatsu A, Kato Y, et al. Growth hormone responses to oral glucose loading measured by highly sensitive enzyme immunoassay in normal subjects and patients with glucose intolerance and acromegaly. J Clin Endocrinol Metab. 1990;70(3):771–6.
Earll JM, Sparks LL, Forsham PH. Glucose suppression of serum growth hormone in the diagnosis of acromegaly. JAMA. 1967;201(8):628–30.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Ergin, A., Hamrahian, A., Kennedy, A., Gupta, M. (2015). Growth Hormone Suppression Test (Post-Glucose Administration). In: The Cleveland Clinic Manual of Dynamic Endocrine Testing. Springer, Cham. https://doi.org/10.1007/978-3-319-13048-4_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-13048-4_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-13047-7
Online ISBN: 978-3-319-13048-4
eBook Packages: MedicineMedicine (R0)